title: What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma.
abstract: Checkpoint inhibitors have demonstrated remarkable efficacy in patients with chemotherapy-resistant Hodgkin lymphoma. However, it remains unclear whether these impressive agents have curative potential or whether relapse and death will eventually occur. In the present review, we discuss the options for a therapeutic dilemma that is likely to occur with increasing frequency, what to do for a patient with Hodgkin lymphoma who is responding to the checkpoint inhibitors? We discuss the 4 most likely considered options: continuation of checkpoint blockade, cessation of therapy with potential retreatment, transplantation, and chimeric antigen receptor T-cell therapy. These options will require evaluation in future clinical trials; however, we propose a decision strategy that could be of use to practicing clinicians until robust data are available.
authors.affiliation: Division of Cancer Medicine, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Amir K
authors.initials: AK
authors.lastname: Issa
authors.affiliation: Division of Cancer Medicine, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: jwestin@mdanderson.org.
authors.forename: Jason R
authors.initials: JR
authors.lastname: Westin
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D019008:Drug Resistance, Neoplasm; D005260:Female; D006689:Hodgkin Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects; D058990:Molecular Targeted Therapy; D009364:Neoplasm Recurrence, Local; D000072078:Positron Emission Tomography Computed Tomography; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D061026:Programmed Cell Death 1 Receptor
keywords: Checkpoint inhibitors; HL; Nivolumab; Programmed death inhibitor; Transplant